Helping projects
change the future
APPLY NOW

News

Portfolio project going IPO

30 September 2021

Acticor Biotech, Primer Capital's portfolio project, announces its projected IPO on the Euronext Growth market in Paris

Portfolio project going IPO

Acticor Biotech, Primer Capital's portfolio project, announces its projected IPO on the Euronext Growth market in Paris
 

Primer Capital at the Sirius Summit

10 May 2021

On April 26-30, 2021, Anton Lavrentiev, CEO of Primer Capital took part in the Big Challenges Summit at Sirius as a speaker in the mini-symposium "Technology Entrepreneurship: The Path to the New Economy".

Primer Capital at the Sirius Summit

On April 26-30, 2021, Anton Lavrentiev, CEO of Primer Capital took part in the Big Challenges Summit at Sirius as a speaker in the mini-symposium "Technology Entrepreneurship: The Path to the New Economy".
 

Primer Capital CEO spoke at the Russian Venture Forum in Kazan

9 April 2021

Anton Lavrentiev at the "Venture Capital Market 2020: Trends and Challenges" panel at the central event of the Russian venture capital industry in Kazan.

Primer Capital CEO spoke at the Russian Venture Forum in Kazan

Anton Lavrentiev at the "Venture Capital Market 2020: Trends and Challenges" panel at the central event of the Russian venture capital industry in Kazan.
 

ATLAS has become the first in Russia to register a test which detects 6 oncogenes simultaneously

18 March 2021

Primer Capital portfolio project, Atlas has become the first company in Russia to receive marketing authorization for its kit which can simultaneously detect 6 mutations in the BRAF, EGFR, KRAS, NRAS, KIT, PDGFRA genes in tumor samples.

ATLAS has become the first in Russia to register a test which detects 6 oncogenes simultaneously

Primer Capital portfolio project, Atlas has become the first company in Russia to receive marketing authorization for its kit which can simultaneously detect 6 mutations in the BRAF, EGFR, KRAS, NRAS, KIT, PDGFRA genes in tumor samples.
 

Primer Capital's CEO Spoke at the Private Equity and M&A Conference

15 February 2021

The CEO of Primer Capital, Anton Lavrentiev, spoke at the Private Equity and M&A conference on February 11-12, 2021.

Primer Capital's CEO Spoke at the Private Equity and M&A Conference

The CEO of Primer Capital, Anton Lavrentiev, spoke at the Private Equity and M&A conference on February 11-12, 2021.
 

Primer Capital's portfolio project closed an investment round

23 December 2020

Botkin.AI, a platform for analyzing and processing CT scans using AI using raised RUB 160 million in a round of funding.

Primer Capital's portfolio project closed an investment round

Botkin.AI, a platform for analyzing and processing CT scans using AI using raised RUB 160 million in a round of funding.
 

Primer Capital is the winner of the National Venture Investor Award 2020

28 October 2020

The fund won the Best Syndicated Deal nomination for its investment in Botkin.AI project

Primer Capital is the winner of the National Venture Investor Award 2020

The fund won the Best Syndicated Deal nomination for its investment in Botkin.AI project
 

Acticor Biotech Announces the Success of its Phase I study with Glenzocimab In Patients with Acute Ischemic Stroke

1 October 2020

Primer Capital's portofolio project, a France-based clinical stage biotechnology company today announced the completion of its Dose Escalation Phase of Glenzocimab Study.

Acticor Biotech Announces the Success of its Phase I study with Glenzocimab In Patients with Acute Ischemic Stroke

Primer Capital's portofolio project, a France-based clinical stage biotechnology company today announced the completion of its Dose Escalation Phase of Glenzocimab Study.
 

Primer Capital’s Portfolio Project has filed for an IPO

4 September 2020

US-based Athira Pharma, a project financed by Primer Capital, is planning to go public.

Primer Capital’s Portfolio Project has filed for an IPO

US-based Athira Pharma, a project financed by Primer Capital, is planning to go public.
 

Portfolio project becomes a winner of AstraZeneca Skolkovo Accelerator

3 July 2020

The GemoPharm company was announced the winner of the scientific track within the acceleration program by AstraZeneca Skolkovo StartUp Challenge 2020.

Portfolio project becomes a winner of AstraZeneca Skolkovo Accelerator

The GemoPharm company was announced the winner of the scientific track within the acceleration program by AstraZeneca Skolkovo StartUp Challenge 2020.

Записи 1 - 10 of 71
First | Prev. | 1 2 3 4 5 | Next | Last